Massachusetts Financial Services Co. MA Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Massachusetts Financial Services Co. MA lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,396,032 shares of the medical research company's stock after selling 179,599 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.63% of Thermo Fisher Scientific worth $1,192,266,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $25,000. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at $30,000. Cassady Schiller Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after acquiring an additional 33 shares during the last quarter. VSM Wealth Advisory LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $36,000. Finally, Navigoe LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $37,000. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent analyst reports. Royal Bank Of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research note on Friday. UBS Group lowered shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $500.00 to $460.00 in a report on Tuesday, July 8th. Argus lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Finally, Robert W. Baird reduced their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $600.30.

Thermo Fisher Scientific Stock Down 2.2%

NYSE TMO traded down $9.42 during mid-day trading on Monday, reaching $425.44. The stock had a trading volume of 2,819,329 shares, compared to its average volume of 2,412,383. The company has a fifty day moving average price of $409.39 and a 200 day moving average price of $475.87. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The stock has a market cap of $160.60 billion, a PE ratio of 24.95, a price-to-earnings-growth ratio of 2.31 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the firm posted $5.11 earnings per share. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's payout ratio is 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.